Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer

Immunovia AB Sweden

 
Karin Almqvist Liwendahl
Chief Financial Officer
[e-mail] 
[phone]

Immunovia in brief 

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. 

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. 

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. 

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit?www.immunovia.com 

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/immunovia-ab/r/immunovia-has-successfully-acquired-all-blood-samples-required-to-clinically-validate-its-next-gener,c4047677

The following files are available for download:

https://mb.cision.com/Main/13121/4047677/3040639.pdf

Press release (PDF)

 

View original content:https://www.prnewswire.co.uk/news-releases/immunovia-has-successfully-acquired-all-blood-samples-required-to-clinically-validate-its-next-generation-test-for-pancreatic-cancer-302268676.html

@ prnewswire.co.uk